FDA approves osteoporosis therapy for high-risk postmenopausal women

(HealthDay)—Evenity (romosozumab-aqqg) was approved for the treatment of osteoporosis in postmenopausal women with a high risk for fracture, the U.S. Food and Drug Administration announced.
Read More